About
Curesponse develops a functional and genomic precision oncology test that evaluates the effectiveness of cancer therapies on patient biopsies to guide personalized treatment selection, primarily focusing on solid tumors.
Explore Curesponse's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.